Based on the abovementioned results, GnRH antagonist effects on reducing VEGF levels during COS may be more noticeable in the PCOS subjects due to the ovarian angiogenesis abnormality seen in this population. This evidence concerns the gene VEGFA and polycystic ovary syndrome.